Dazhong Mining's (SHE:001203) subsidiary, Anhui Jinrisheng Mining, agreed to borrow 250 million yuan from Bank of China's (SHA:601988, HKG:3988) Lu'an branch, according to a Shenzhen bourse filing on Friday.
Dazhong Mining serves as the guarantor for the loan.
The mining company's available guarantee balance for Jinrisheng Mining reduced to 1.20 billion yuan from 1.45 billion yuan.
Dazhong's shares jumped 3% during the midday trade.
DL Holdings (HKG:1709) said C Capital AI agreed to invest $1.5 million in ARTi Holding through a pre-A funding round, according to a Thursday Hong Kong bourse filing.The investor will subscribe for 500 new Class B shares, implying a pre-money valuation of $30 million for the artificial intelligence investment research platform.Following the transaction, DL Holdings' stake in ARTi will be diluted to about 47.6% from 50%.
CF PharmTech (HKG:2652) said its inhalation formulation production base in Suzhou passed a good manufacturing practice inspection conducted by the drug regulator of a member country of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, according to a Thursday Hong Kong bourse filing.The inspection covered the facility's production management and quality control systems, premises, equipment, data integrity, and computerized systems.Shares of the pharmaceutical firm were up over 1% in Friday morning trade.
Pharmaceutical company Lupin (NSE:LUPIN, BOM:500257) has received approval from the U.S. Food and Drug Administration for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis of Genentech.The US FDA has approved Ranluspec in both vials and pre-filled syringes in strengths of 0.3 mg (0.05 mL of 6 mg/mL) and 0.5 mg (0.05 mL of 10 mg/mL).The drug is used to treat adults with certain sight problems, including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularisation.